These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34962713)

  • 1. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
    Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
    Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic interobserver agreement for thyroid fine-needle aspirates: Effects of reviewer experience and molecular diagnostics.
    Gokozan HN; Mostyka M; Scognamiglio T; Solomon JP; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
    Am J Clin Pathol; 2024 Sep; 162(3):302-313. PubMed ID: 38656386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combined Use of Fine-Needle Aspiration (FNA) and BRAF V600E Gene Testing: Can it Increase the Definitive Diagnosis Rate of Nodules Categorized as Bethesda III for Papillary Thyroid Carcinoma?
    Lei L; Hong Qing S; Wei L; Ma Mo Yang F; Xiao Xiang Y
    Am Surg; 2024 Dec; 90(12):3209-3215. PubMed ID: 39047144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J; Ahn S; Shin JH; Oh YL
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
    Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
    Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
    Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
    Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
    [No Abstract]   [Full Text] [Related]  

  • 9. Atypia of undetermined significance and ThyroSeq v3-positive call rates as quality control metrics for cytology laboratory performance.
    Mejia-Mejia O; Bravo-Gonzalez A; Sanchez-Avila M; Tjendra Y; Santoscoy R; Drews-Elger K; Zuo Y; Arias-Abad C; Gomez C; Garcia-Buitrago M; Nadji M; Jorda M; Velez-Torres JM; Ruiz-Cordero R
    Cancer Cytopathol; 2024 Aug; 132(8):481-490. PubMed ID: 38594192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
    Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
    Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
    Hall EA; Hartzband P; VanderLaan PA; Nishino M
    Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
    Wu H; Zhang B; Cai G; Li J; Gu X
    PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
    Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
    Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio: a proposed performance measure for reporting in The Bethesda System for thyroid cytopathology.
    Krane JF; Vanderlaan PA; Faquin WC; Renshaw AA
    Cancer Cytopathol; 2012 Apr; 120(2):111-6. PubMed ID: 21919213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF
    Chirayath SR; Pavithran PV; Abraham N; Nair V; Bhavani N; Kumar H; Menon UV; Menon AS
    Indian J Endocrinol Metab; 2019; 23(3):278-281. PubMed ID: 31641627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Young investigator challenge: Atypia of undetermined significance in thyroid FNA: Standardized terminology without standardized management--a closer look at repeat FNA and quality measures.
    Brandler TC; Aziz MS; Coutsouvelis C; Rosen L; Rafael OC; Souza F; Jelloul FZ; Klein MA
    Cancer Cytopathol; 2016 Jan; 124(1):37-43. PubMed ID: 26765064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [On-site fine-needle aspiration cytology of thyroid nodules. Quality assurance of the Bethesda System for Reporting Thyroid Cytopathology (2008)].
    Bak M; Péter I; Nyári T; Simon P; Újlaky M; Boér A; Kásler M
    Orv Hetil; 2015 Oct; 156(41):1661-6. PubMed ID: 26551169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Large Thyroid Fine Needle Aspiration Biopsy Cohort with Long-Term Population-Based Follow-Up.
    Ng DL; van Zante A; Griffin A; Hills NK; Ljung BM
    Thyroid; 2021 Jul; 31(7):1086-1095. PubMed ID: 33371796
    [No Abstract]   [Full Text] [Related]  

  • 20. Application of the Bethesda Classification for Thyroid Fine-Needle Aspiration: Institutional Experience and Meta-analysis.
    Krauss EA; Mahon M; Fede JM; Zhang L
    Arch Pathol Lab Med; 2016 Oct; 140(10):1121-31. PubMed ID: 27684984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.